Acrivon Therapeutics, Inc.
ACRV
$1.52
-$0.06-3.80%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -18.99M | -18.23M | -21.01M | -19.68M | -22.83M |
| Total Depreciation and Amortization | 361.00K | 349.00K | 335.00K | 311.00K | 303.00K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 3.49M | 4.14M | 4.01M | 3.68M | 3.05M |
| Change in Net Operating Assets | -99.00K | 1.47M | 52.00K | -3.85M | 2.12M |
| Cash from Operations | -15.24M | -12.28M | -16.61M | -19.54M | -17.36M |
| Capital Expenditure | -219.00K | -899.00K | -493.00K | -58.00K | -827.00K |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 21.74M | 6.81M | 19.94M | 19.27M | 15.24M |
| Cash from Investing | 21.52M | 5.91M | 19.45M | 19.21M | 14.41M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 0.00 | 0.00 | 0.00 | 1.00K | 0.00 |
| Repurchase of Common Stock | -192.00K | -117.00K | -97.00K | -344.00K | -647.00K |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | 0.00 |
| Cash from Financing | -192.00K | -117.00K | -97.00K | -343.00K | -647.00K |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 6.10M | -6.49M | 2.74M | -664.00K | -3.60M |